How does Olumiant compare to other JAK inhibitors
Palmetto Specialty Pharm
A dually accredited, 50 state licensed specialty pharmacy singularly focused on improving the patient's health journey.
Olumiant (baricitinib) is one of several Janus kinase (JAK) inhibitors used to treat autoimmune conditions. Here's how it compares to other JAK inhibitors:
Mechanism of Action
Olumiant is a potent JAK1 and JAK2 inhibitor with minimal activity on JAK3[2]. This differs from other JAK inhibitors like Xeljanz (tofacitinib), which has the greatest affinity for JAK3 and is considered a pan-JAK inhibitor (JAK3>JAK1>JAK2)[2].
Indications
Olumiant is approved for rheumatoid arthritis, atopic dermatitis, and COVID-19 treatment in hospitalized adults[1][2]. In contrast, Xeljanz has a broader range of FDA-approved indications, including ulcerative colitis[1].
Dosing
Olumiant is typically taken once daily, while Xeljanz is usually dosed twice daily[1].
Efficacy
A network meta-analysis found that upadacitinib 15 mg once daily had numerically higher efficacy in terms of ACR response and clinical remission among approved JAK inhibitors for rheumatoid arthritis[6]. However, direct head-to-head studies comparing JAK inhibitors are lacking, making it difficult to definitively state their comparative effectiveness.
Safety Profile
Recent studies have raised concerns about the safety of JAK inhibitors:
1. A clinical trial with Xeljanz showed higher risks of major adverse cardiovascular events (MACE), thrombosis, malignancy, serious infections, and fatal events compared to TNF inhibitors in rheumatoid arthritis patients[3].
2. Preliminary results from an observational study suggest Olumiant is associated with higher risks of MACE and thrombosis compared to TNF inhibitors in rheumatoid arthritis patients[3][4].
领英推荐
3. The European Medicines Agency (EMA) concluded that these identified risks apply to all JAK inhibitors approved for chronic inflammatory disorders[4].
Conclusion
While Olumiant shares similarities with other JAK inhibitors, it has a unique inhibitory profile and specific approved indications. The choice between Olumiant and other JAK inhibitors should be made in consultation with a healthcare provider, considering individual patient factors, efficacy, and potential risks.
Citations: